NEW YORK (360Dx) – Chembio Diagnostics said today that it has received CE marking for its DPP HIV-Syphilis combination assay — a single-use, point-of-care test for the detection of antibodies to HIV 1 and 2 and Treponema pallidum, the causative agent of syphilis.

The assay — cleared for marketing within the member states of the European Union, and the Caribbean region except for Puerto Rico — runs on the firm's Dual Path Platform chromatographic immunoassay technology, which has significant advantages over lateral flow technologies, Chembio said.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.


In this webinar, Jill Viles, an Iowa mother with no clinical training, shares her story of how she self-diagnosed her rare condition, a muscle-wasting disease caused by a mutation in the LMNA gene. She will also discuss how she discovered that a mutation in the same gene is the underlying cause for the excess muscle phenotype exhibited by Canadian Olympic hurdler Priscilla Lopes-Schliep.